Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 10:00:37 15/01/2025 GMT			5-day change	1st Jan Change
19.84 ^EUR	+1.19%		+0.83%	+2.67%

10:32am	Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	MT
09:18am	Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	DP

BAYER : 2025: another year without a catalyst?

November 13, 2024 at 11:14 am

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Bayer AG

Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	09:32am	MT
Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	08:18am	DP
After Asundexian setback: Bayer optimistic about new blockbusters	06:23am	RE
Another setback: Bayer ordered to pay damages in PCB trial	05:36am	RE
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	05:15am	MT
Bayer Aktiengesellschaft Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	01-14
Bayer pharma chief sees no big acquisitions in near future	01-14	RE
Bayer: first participants in AskBio trial	01-14	CF
Bayer continues to focus on revitalizing its pharmaceuticals business in the medium term – no major deals	01-14	DP
Bayer will focus on debt reduction rather than acquisitions in the coming years	01-14	RE
German Stocks Retreat Amid US Rate Jitters	01-13	MT
Bayer to Commence Late-stage Study for Parkinson's Disease Therapy	01-13	MT
Bayer: towards a Phase III study in Parkinson's disease	01-13	CF
Bayer is starting a crucial cell therapy study for Parkinson's disease	01-13	RE
Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar	01-13	MT
Farmers see difficult business situation in 2025	01-11	DP
Bayer Announces Positive Topline Results of the Pivotal Phase III Quanti Studies Evaluating the Efficacy and Safety of Gadoquatrane, an Investigational Gadolinium-Based Contrast Agent for Use in Magnetic Resonance Imaging	01-10	CI
Bayer Files Marketing Authorization Applications for New Indication of Finerenone in US, China	01-10	MT
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA®	01-10	CI
Bayer: positive results for an MRI contrast agent	01-10	CF
Bayer's MRI Contrast Agent Meets Primary, Secondary Endpoints in Late-stage Studies	01-10	MT
German Stocks Muted Amid Local Economic Data Focus	01-09	MT
Bayer to Buy Smart Earth Camelina's Oilseed Crop	01-09	MT
Bayer: completes acquisition of Camelina assets	01-09	CF
Bayer: new positive data for elinzanetant	01-09	CF

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

21/01/2025 - UniCredit Kepler Cheuvreux German Corporate Conference

More about the company